Guangzhou United Family Brings Beizray — a Tween-80-Free Docetaxel — to Cancer Patients

Through the Greater Bay Area’s HK–Macau Drugs & Devices (港澳药械通) channel, Guangzhou United Family Hospital is now offering Beizray® — a novel, albumin-bound, Tween-80-free formulation of docetaxel — to patients with breast, lung, head-and-neck, gastric, prostate, gynecologic and other solid tumors. The hospital’s oncology team points to a clinical record that is, in two distinct ways, “better than traditional docetaxel” — markedly lower haematological toxicity and no need for steroid pre-medication.

Why chemotherapy remains the backbone

Even in the era of targeted therapy, immunotherapy and antibody-drug conjugates, chemotherapy remains indispensable. It has unmatched broad-spectrum coverage — vital for patients without an actionable driver mutation — and spans the entire treatment journey, from neoadjuvant and adjuvant therapy to advanced palliative care. It also pairs well with newer modalities: chemotherapy + targeted, chemotherapy + immunotherapy and chemotherapy + ADCs frequently deliver stronger combination outcomes than any single modality alone.

A 60-year foundation: docetaxel’s evolution

Docetaxel — the second-generation taxane — was first isolated from European yew needles by the team of Pierre Potier in 1980, patented in 1986 and launched by Sanofi as Taxotere® in 1995. It is now used in 90+ countries and recommended by every major oncology guideline (NCCN, CSCO, CACA) across breast cancer (early neoadjuvant, adjuvant, first-line and beyond), non-small-cell lung cancer (with cisplatin as first-line for non-squamous; maintenance; chemo-radiation for locally advanced), head-and-neck (induction, first and second line), prostate (metastatic castration-resistant mCRPC; metastatic castration-sensitive mCSPC), gastric / GEJ (neoadjuvant, first and second line), ovarian / cervical / endometrial, esophageal, SCLC, bladder, and soft-tissue sarcoma.

Visual: NCCN / CSCO / CACA guidelines for docetaxel — breast cancer, NSCLC, head-and-neck, prostate, gastric / GEJ, gynecologic tumors, esophageal, SCLC, bladder, soft-tissue sarcoma.

The “Achilles heel” of traditional docetaxel

Docetaxel is poorly water-soluble, so traditional formulations use polysorbate 80 (Tween-80) as a solubiliser. This creates two persistent clinical problems:

• Tween-80 is a strong allergen and can trigger severe hypersensitivity reactions — requiring all patients to undergo heavy steroid pre-medication.
• Tween-80 also competes with docetaxel for albumin-binding sites in the blood, raising free drug concentrations and increasing bone-marrow suppression.
• The required pre-medication steroids bring further glucose-fluctuation risks for diabetic patients.

These drawbacks limit the use of traditional docetaxel in elderly or frail patients. Until now, China has had no approved Tween-80-free docetaxel available — leaving a meaningful unmet need for patients who are allergic to Tween-80 or cannot tolerate steroid pre-medication.

How Beizray works: albumin, not Tween-80

Beizray binds docetaxel to natural human serum albumin in a single-molecule, non-covalent complex smaller than 1 nm. This approach sidesteps Tween-80 entirely and gives the drug a fundamentally different pharmacokinetic profile:

• Circulation. Docetaxel pre-binds albumin before infusion, lowering free-drug levels in plasma — reducing non-tumor toxicity.
• Tumour targeting. The albumin–docetaxel complex uses the GP60–SPARC pathway to concentrate docetaxel in tumour tissue — substantially improving tumour exposure while sparing haematopoietic cells.
• Drug release. Once inside tumour cells, docetaxel fully inhibits microtubule disassembly, arresting tumour cells in the G2/M phase and triggering apoptosis.

Clinical evidence: Phase I and bioequivalence

Phase I dose-escalation (Wang J et al., J Clin Oncol 2024;42(16_suppl):e17545)

A study in late-stage head-and-neck squamous-cell carcinoma and ovarian cancer patients (N = 11) who could not tolerate weekly traditional docetaxel established that Beizray every 4 weeks, without steroid pre-medication, was feasible — with a maximum tolerated dose (MTD) and overall tolerability that were both better than the traditional comparator.

Bioequivalence (Sun Q et al., J Clin Oncol 2023;41(16_suppl):e13002)

A 41-patient, multi-centre, open-label, randomised, single-dose, two-way crossover BE study confirmed that, at the same dose, Beizray is bioequivalent to Taxotere — comparable C_max, AUC_0–t, and AUC_0–inf for both total and free docetaxel. The two key safety advantages emerged in the same trial:

Why this matters for patients

• No Tween-80, no box warning. The albumin vehicle removes the heavy steroid pre-medication regimen and its glucocorticoid-related side effects — a meaningful change for diabetic patients or those managing active infection.
• Less bone-marrow suppression. Grade 3/4 cytopenias drop from ~16% to ~2%, meaning fewer dose delays, transfusions or growth-factor rescues.
• Higher tolerable doses → better efficacy. Improved tolerability supports more consistent dose intensity and prolonged treatment continuity.
• Fills a regulatory gap. Beizray is the first multi-cancer Tween-80-free docetaxel option accessible in mainland China (via the HK–Macau channel) — including head-and-neck squamous-cell carcinoma, where no docetaxel formulation had previously been approved.

Access via the HK–Macau Drugs & Devices channel

As a designated institution under 港澳药械通, Guangzhou United Family Hospital can introduce Beizray ahead of mainstream national approval. Guangzhou UFH’s oncology department — known among its peers for an ongoing “top drug + full journey” model — has used the policy to bring multiple breakthrough international oncology drugs to patients ahead of broader market availability.

Source: Guangzhou United Family Hospital WeChat article, 7 Sep 2026. References: Wang J et al., J Clin Oncol 2024;42(16_suppl):e17545; Sun Q et al., J Clin Oncol 2023;41(16_suppl):e13002.